



AGENDA

Pharmaceuticals & Therapeutics Committee

Department of Health Care Policy & Financing

Zoom Webinar

https://magellanhealth.zoom.us/webinar/register/WN_NxFWWiXXSCitvSqlAUkYxw

April 13, 2021, 1:00-5:00 P.M.

1. Committee Member Introductions

James Feinstein, MD, Chairperson

Gwen Black, PharmD, Vice Chair

Lynn Parry, MD

Kimberley Jackson, DO

Marisa Wiktor, MD

David Elwell, MD

Kelet Robinson, MD

Emily Kosirog, PharmD

Thuy McKittrick, PharmD

Daralyn Morgenson, PharmD

Davin Patel, PharmD

2. Unfinished Business and General Orders

Approval of minutes from January 12, 2021 P&T meeting

Updates from January 12, 2021 P&T Meeting

- Diabetes Management - Insulins
- Glucagon, Self-Administered
- Lipotropics
- Cardiovascular Agents
 - Alpha-Blockers
 - Beta-Blockers & Combinations
 - Calcium Channel Blockers
- Leukotriene Modifiers
- Multiple Sclerosis Agents
- Anti-Parkinson's Agents
 - Dopa Decarboxylase Inhibitors & Combinations
 - MAO-Bs
 - Dopamine Agonists
 - Other
- Antimigraine Agents - Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- Atypical Antipsychotics
- Sedative Hypnotics
 - Non-Benzodiazepine
 - Benzodiazepine
- Anxiolytics
- Anorectal, Hemorrhoidal and Other Topical Anesthetic Agents



- Ophthalmic Anti-Inflammatories
- Ophthalmic Glaucoma Agents
- Mass review drug classes:
 - Statins & Statin Combinations
 - Lithium Agents
 - Neurocognitive Disorder Agents
 - Topical Steroids
 - Low Potency
 - Medium Potency
 - High Potency
 - Very High Potency
 - Growth Hormones
 - Bile Salts
 - Immune Globulins
 - Intranasal Rhinitis Agents
 - Ophthalmic Allergy Agents

3. New Business

Updates from the Prior Authorization Call Center

4. Drug Classes Up for Review

Review of Non-Opioid Analgesics

Review of Opioids - Short-Acting

Review of Fentanyl Preparations

Review of Opioids - Long-Acting

Review of Angiotensin modulators and Angiotensin modulator combinations

- ACEIs, ACEI Combinations
- ARBs, ARB Combinations
- Renin Inhibitors & Combinations

Review of Acne Agents, Topical

Review of Acne Agents, Oral Isotretinoin

Review of Antineoplastics, Topical

Review of Rosacea Agents

Review of Phosphate Binders

Review of Respiratory Inhalants

- Inhaled Anticholinergics & Anticholinergic Combinations
- Inhaled Beta₂ Agonists (short & long-acting)
- Inhaled Corticosteroids and Combinations
- Phosphodiesterase Inhibitors (PDEIs)

Mass review drug classes:

- Review of Tetracyclines
- Review of Skeletal Muscle Relaxants

Improving health care equity, access and outcomes for the people we serve while saving Coloradans money on health care and driving value for Colorado.

www.colorado.gov/hcpf



- Review of Topical Immunomodulators
- Review of Androgenic Agents - Topicals, Injectables, Orals
- Review of Antihistamines, Newer Generation & Combinations
- Review of Benign Prostatic Hypertrophy (BPH) Agents

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical information that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, jlczechowski@magellanhealth.com and carbon copy: Brittany Schock, PDL Pharmacist, brittany.schock@state.co.us. Once approved, public comments will be distributed to P&T Committee Members. Due to Virtual venue change, provide public comments were due by **April 6th, 2021 by 5pm MST**.

5. Adjourn

Upcoming Meeting Date: Tuesday, July 13, 2021; 1:00 p.m. - 5:00 p.m.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

